Listen
NOCDURNA (desmopressin), vasopressin analogue
UROLOGY - New medicinal product
Opinions on drugs -
Posted on
Aug 02 2017
Reason for request
Inclusion
Insufficient clinical benefit in the treatment of nocturia associated with idiopathic nocturnal polyuria in the absence of any role in the therapeutic strategy
- NOCDURNA has Marketing Authorisation in treatment of nocturia in adults, when it is associated with idiopathic nocturnal polyuria.
- The impact on quality of life has not been demonstrated.
- The efficacy on the reduction of urination, compared with placebo, was low and without clinical relevance. It was established short-term in patients with low severity. The transferability to an older population with greater severity is not assured.
- There is a risk of severe hyponatraemia due to drug interactions with desmopressin in elderly patients on multiple medications.
Clinical Benefit
| Insufficient |
- |
Therapeutic use
- |
English version
Contact Us
Évaluation des médicaments
